Medgenics, Inc.
('Medgenics' or the 'Company')
Issue of Equity
8 February 2010
The Company announces that, pursuant to an agreement between the Company and Equity Source Partners, LLC ("ESP") dated 1 May 2009, on 19 January 2010 a Board resolution was passed to issue and allot 1,275,000 common US $0.0001 shares in the Company ("Common Shares") conditional upon admission to trading on AIM. The Common Shares were issued as compensation for services rendered to the Company by ESP. Application has now been made to the London Stock Exchange for the new Common Shares to be admitted to trading on AIM. Dealings are expected to commence at 8.00 a.m. on 9 February 2010.
Following the admission to trading of the new Common Shares, the Company's total issued share capital will be 123,449,027* Common Shares and the percentage of AIM Securities not in public hands will be 28.9%*.
Note
* Excluding any Common Shares issued pursuant to the block admission between 4 December 2009 and the date of this announcement and the 192,591 new Common Shares which certain directors of the Company irrevocably agreed to subscribe for on 5 February 2010.
For further information, contact:
Medgenics, Inc. +972 4 902 8900
Dr. Andrew L. Pearlman
De Facto Communications +44 20 7861 3838
Mike Wort m.wort@defacto.com
Anna Dunphy a.dunphy@defacto.com
Grayling (Investor Relations - US) +1 646 284 9472
Leslie Wolf-Creutzfeldt lwolf-creutzfeldt@hfgcg.com
Blomfield Corporate Finance (Nomad) +44 207 444 0800
James Pinner
Alan MacKenzie
SVS Securities plc (Broker) +44 207 638 5600
Peter Manfield
About Medgenics:
Medgenics is a clinical-stage biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. The Company currently has three products in development based on this technology and addressing the indications of:
- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO)
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a)
- Haemophilia - using a Biopump to produce clotting Factor VIII
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in patients with chronic kidney disease, has demonstrated proof of concept of the Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for six months or more, EPODURE Biopumps have already provided effectiveanaemia treatment in most of these patients for 6-12 months, even at the low administered dose.
Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major pharmaceutical and/or medical device companies. In addition to treatments for Anemia, Hepatitis-C, Hemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach US $87 billion by 2010. Other potential applications of Biopumps producing various proteins include multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity, and diabetes